Published in J Clin Pathol on February 01, 2005
Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo. J Physiol (2006) 2.28
Normal myoblast fusion requires myoferlin. Development (2005) 1.97
Dysferlin and muscle membrane repair. Curr Opin Cell Biol (2007) 1.82
Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet (2010) 1.81
Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol (2008) 1.65
Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest (2010) 1.23
Dysferlin stabilizes stress-induced Ca2+ signaling in the transverse tubule membrane. Proc Natl Acad Sci U S A (2013) 1.21
Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One (2012) 1.10
Dystrophin deficiency exacerbates skeletal muscle pathology in dysferlin-null mice. Skelet Muscle (2011) 1.06
Myoferlin is required for insulin-like growth factor response and muscle growth. FASEB J (2009) 0.99
Ferlin proteins in myoblast fusion and muscle growth. Curr Top Dev Biol (2011) 0.98
Lysosome fusion to the cell membrane is mediated by the dysferlin C2A domain in coronary arterial endothelial cells. J Cell Sci (2012) 0.95
Dysferlin regulates cell membrane repair by facilitating injury-triggered acid sphingomyelinase secretion. Cell Death Dis (2014) 0.94
The muscle protein dysferlin accumulates in the Alzheimer brain. Acta Neuropathol (2006) 0.91
Distinct effects of contraction-induced injury in vivo on four different murine models of dysferlinopathy. J Biomed Biotechnol (2012) 0.85
Myogenesis in dysferlin-deficient myoblasts is inhibited by an intrinsic inflammatory response. Neuromuscul Disord (2012) 0.84
Translational research and therapeutic perspectives in dysferlinopathies. Mol Med (2011) 0.82
Diagnosis by protein analysis of dysferlinopathy in two patients mistaken as polymyositis. Acta Myol (2011) 0.81
Myofiber damage precedes macrophage infiltration after in vivo injury in dysferlin-deficient A/J mouse skeletal muscle. Am J Pathol (2015) 0.78
Biochemical and ultrastructural evidence of endoplasmic reticulum stress in LGMD2I. Virchows Arch (2007) 0.78
Enhanced Muscular Dystrophy from Loss of Dysferlin Is Accompanied by Impaired Annexin A6 Translocation after Sarcolemmal Disruption. Am J Pathol (2016) 0.77
Upregulated IL-1β in dysferlin-deficient muscle attenuates regeneration by blunting the response to pro-inflammatory macrophages. Skelet Muscle (2015) 0.76
Polymyositis without Beneficial Response to Steroid Therapy: Should Miyoshi Myopathy be a Differential Diagnosis? Am J Case Rep (2017) 0.75
The absence of dysferlin induces the expression of functional connexin-based hemichannels in human myotubes. BMC Cell Biol (2016) 0.75
Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature (2003) 6.50
Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem (2003) 3.00
Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet (2004) 2.32
Limb-girdle muscular dystrophies--from genetics to molecular pathology. Neuropathol Appl Neurobiol (2004) 1.71
The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum Mol Genet (2001) 1.63
Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology (2001) 1.60
The 10 autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord (2003) 1.58
Repairing a torn cell surface: make way, lysosomes to the rescue. J Cell Sci (2002) 1.48
Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol (2003) 1.35
Gene expression profiling in dysferlinopathies using a dedicated muscle microarray. Hum Mol Genet (2002) 1.32
The earliest pathologic alterations in dysferlinopathy. Neurology (2001) 1.28
Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol (2002) 1.27
Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency. Am J Pathol (2002) 1.24
Repairing the tears: dysferlin in muscle membrane repair. Trends Mol Med (2003) 1.21
Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb--girdle muscular dystrophies. Ann Neurol (2000) 1.18
Dysferlin in a hyperCKaemic patient with caveolin 3 mutation and in C2C12 cells after p38 MAP kinase inhibition. Exp Mol Med (2003) 0.89
Up-regulation of MHC class I expression accompanies but is not required for spontaneous myopathy in dysferlin-deficient SJL/J mice. Am J Pathol (2002) 0.88
Membrane-repair machinery and muscular dystrophy. Lancet (2003) 0.84
Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet (1998) 4.38
SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology (2010) 3.37
MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. Proc Natl Acad Sci U S A (1992) 2.82
Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet (1991) 2.79
Correlating phenotype and genotype in the periodic paralyses. Neurology (2004) 2.55
Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet (1995) 2.53
MELAS: clinical features, biochemistry, and molecular genetics. Ann Neurol (1992) 2.48
Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science (1973) 2.34
Fingerprint body myopathy, a newly recognized congenital muscle disease. Mayo Clin Proc (1972) 2.34
Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord (2009) 2.13
Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun (1995) 2.06
Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology (2005) 1.90
Myotonic dystrophy: evidence for a possible dominant-negative RNA mutation. Hum Mol Genet (1995) 1.89
Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med (1997) 1.82
Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology (1989) 1.81
Type 1 fiber abnormalities in skeletal muscle of patients with hypertrophic and dilated cardiomyopathy: evidence of subclinical myogenic myopathy. J Am Coll Cardiol (1989) 1.76
Cerebellar ataxia and coenzyme Q10 deficiency. Neurology (2003) 1.73
Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. Neurology (1995) 1.62
Retrospective study on PET-SPECT imaging in a large cohort of myotonic dystrophy type 1 patients. Neurol Sci (2010) 1.58
Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation (1996) 1.54
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Laminin alpha2 muscular dystrophy: genotype/phenotype studies of 22 patients. Neurology (1998) 1.42
Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy. Hum Mol Genet (1996) 1.39
A stop-codon mutation in the human mtDNA cytochrome c oxidase I gene disrupts the functional structure of complex IV. Am J Hum Genet (1999) 1.36
Cardiac involvement in Becker muscular dystrophy. J Am Coll Cardiol (1993) 1.36
Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet (2009) 1.35
Correlation between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy. J Am Coll Cardiol (1995) 1.33
A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve (2000) 1.30
Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol (2002) 1.27
Genotype-phenotype correlations of DHP receptor alpha 1-subunit gene mutations causing hypokalemic periodic paralysis. Neuromuscul Disord (1997) 1.24
Genetic epidemiology of congenital muscular dystrophy in a sample from north-east Italy. Hum Genet (1996) 1.24
Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment? J Neuropathol Exp Neurol (2001) 1.21
A point mutation in the 5' splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy. Hum Mol Genet (1996) 1.21
Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology (2009) 1.20
Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy. Neuromuscul Disord (1996) 1.19
TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. Eur J Neurol (2009) 1.18
Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet (2005) 1.15
Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology (2001) 1.13
EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol (2010) 1.13
The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII). Cell Death Differ (2012) 1.11
MtDNA mutations associated with Leber's hereditary optic neuropathy: studies on cytoplasmic hybrid (cybrid) cells. Biochem Biophys Res Commun (1995) 1.11
Evidence for an excess of B→D*τ(-)ν(τ) decays. Phys Rev Lett (2012) 1.10
Molecular diagnosis in LGMD2A: mutation analysis or protein testing? Hum Mutat (2004) 1.10
Screening for mutations in the muscle promoter region and for exonic deletions in a series of 115 DMD and BMD patients. J Med Genet (1992) 1.10
Observation of time-reversal violation in the B0 meson system. Phys Rev Lett (2012) 1.09
Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of Duchenne muscular dystrophy. Ann Neurol (1991) 1.09
Systemic carnitine deficiency--a treatable inherited lipid-storage disease presenting as Reye's syndrome. N Engl J Med (1980) 1.09
Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve (1999) 1.08
Precise measurement of the e+e- --> pi+pi-(gamma) cross section with the initial state radiation method at BABAR. Phys Rev Lett (2009) 1.07
Prevalence of dystrophin-positive fibers in 85 Duchenne muscular dystrophy patients. Neuromuscul Disord (1992) 1.07
Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2. J Neurol (2010) 1.07
Measurement of |V(cb)| and the form-factor slope in B --> Dl- nu(l) decays in events tagged by a fully reconstructed B meson. Phys Rev Lett (2010) 1.05
LGMD2E patients risk developing dilated cardiomyopathy. Neuromuscul Disord (2003) 1.03
Myotonic dystrophy: tissue-specific effect of somatic CTG expansions on allele-specific DMAHP/SIX5 expression. Hum Mol Genet (1999) 1.02
The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy. J Neurol Neurosurg Psychiatry (2006) 1.02
Dystrophin-positive fibers in Duchenne dystrophy: origin and correlation to clinical course. Muscle Nerve (1995) 1.02
X-inactivation patterns in female Leber's hereditary optic neuropathy patients do not support a strong X-linked determinant. Am J Med Genet (1996) 1.00
MRI in the assessment of muscular pathology: a comparison between limb-girdle muscular dystrophies, hyaline body myopathies and myotonic dystrophies. Radiol Med (2010) 0.99
Risk of arrhythmia in type I myotonic dystrophy: the role of clinical and genetic variables. J Neurol Neurosurg Psychiatry (2009) 0.99
Dysferlin mutation analysis in a group of Italian patients with limb-girdle muscular dystrophy and Miyoshi myopathy. Eur J Neurol (2004) 0.99
ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion. Neurology (2011) 0.99
Myophosphorylase deficiency affects muscle mitochondrial respiration as shown by 31P-MR spectroscopy in a case with associated multifocal encephalopathy. J Neurol Sci (1995) 0.98
Duchenne muscular dystrophy. A population study. Hum Genet (1977) 0.98
Biological effects of a neurotoxic pesticide at low concentrations on sea urchin early development. A terathogenic assay. Chemosphere (1998) 0.97
Early ultrastructural and biochemical changes in muscle in dystrophia myotonica. J Neurol Sci (1970) 0.97
Lipid storage myopathies. A review of metabolic defect and of treatment. J Neurol (1976) 0.97
Carnitine deficiency of skeletal muscle: report of a treated case. Neurology (1976) 0.97
Normal myogenesis and increased apoptosis in myotonic dystrophy type-1 muscle cells. Cell Death Differ (2010) 0.97
Comparative study of acid maltase deficiency. Biochemical differences between infantile, childhood, and adult types. Arch Neurol (1972) 0.97
Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations. J Med Genet (1997) 0.97
Cross-reactive protein in Duchenne muscle. Lancet (1989) 0.96
Search for the rare leptonic decay B--->tau-nutau. Phys Rev Lett (2005) 0.96
Duchenne muscular dystrophy: data from family studies. Hum Genet (1980) 0.95
The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B). Neurol Res (2010) 0.95
Clinical-molecular correlation in 104 mild X-linked muscular dystrophy patients: characterization of sub-clinical phenotypes. Neuromuscul Disord (1994) 0.95
Calpain III mutation analysis of a heterogeneous limb-girdle muscular dystrophy population. Neurology (1999) 0.94
Tubular aggregates: sarcoplasmic reticulum origin, calcium storage ability, and functional implications. Muscle Nerve (1985) 0.94
Riboflavin therapy. Biochemical heterogeneity in two adult lipid storage myopathies. Brain (1999) 0.93
Friedreich's disease: V. Variant form with vitamin E deficiency and normal fat absorption. Neurology (1987) 0.93
Memory deficits and retrieval processes in ALS. Eur J Neurol (2003) 0.93
The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients. J Med Genet (2008) 0.92
Adult acid maltase deficiency. Abnormalities in fibroblasts cultured from patients. N Engl J Med (1972) 0.92
Targeted array comparative genomic hybridization--a new diagnostic tool for the detection of large copy number variations in nemaline myopathy-causing genes. Neuromuscul Disord (2012) 0.92
Calpain-3 and dysferlin protein screening in patients with limb-girdle dystrophy and myopathy. Neurology (2001) 0.91
Abnormal expression of dysferlin in skeletal muscle and monocytes supports primary dysferlinopathy in patients with one mutated allele. Eur J Neurol (2010) 0.91
Enzymes of the glycogen cycle and glycolysis in various human neuromuscular disorders. J Neurol Neurosurg Psychiatry (1967) 0.91
RNA metabolism in myotonic dystrophy: patient muscle shows decreased insulin receptor RNA and protein consistent with abnormal insulin resistance. J Clin Invest (1997) 0.91
Interaction between organophosphate compounds and cholinergic functions during development. Chem Biol Interact (2005) 0.90
A new mutation in a family with cold-aggravated myotonia disrupts Na(+) channel inactivation. Neurology (2001) 0.90